title: Long-term weight control study. II (weeks 34 to 104). An open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise.
abstract: Between weeks 34 and 104, we explored different schema for administering fenfluramine plus phentermine in open-label fashion. At week 34, the original placebo group participants began taking fenfluramine plus phentermine (placebo-to-active group). Those receiving fenfluramine plus phentermine between weeks 6 and 34 either continued to receive medication or began targeted intermittent therapy. Participants who did not lose 10% of initial weight received an augmented dose (60 mg fenfluramine plus 30 mg phentermine. The placebo-to-active group lost an additional 9.1 +/- 0.8 kg (mean +/- SEM) in the period from week 34 to week 60. At week 60, they were assigned to either continue medication, intermittent therapy, or augmented therapy. More than 68% (83) of the original participants completed up to study week 104. At that point, overall weight loss was 10.8 +/- 0.7 kg (11.6 +/- 0.8% of initial weight); participants who continued to receive fenfluramine plus phentermine lost 11.6 +/- 0.8 kg, participants receiving intermittent therapy lost 11.6 +/- 1.3 kg, and participants receiving augmented therapy lost 6.5 +/- 1.5 kg. Although 41% of the participants complained of dry mouth, neither serious adverse effects nor evidence of medication abuse appeared. There were 29 dropouts in the period from weeks 34 to 104. Sixteen of those were related to medication (adverse effects, lack of efficacy, and fear of medication). Overall, fenfluramine plus phentermine used in conjunction with behavior modification, caloric restriction, and exercise continued to be efficacious for up to 2 years.
authors.affiliation: Department of Community and Preventive Medicine, University of Rochester School of Medicine and Dentistry, NY.
authors.forename: M
authors.initials: M
authors.lastname: Weintraub
authors.forename: P R
authors.initials: PR
authors.lastname: Sundaresan
authors.forename: B
authors.initials: B
authors.lastname: Schuster
authors.forename: G
authors.initials: G
authors.lastname: Ginsberg
authors.forename: M
authors.initials: M
authors.lastname: Madan
authors.forename: A
authors.initials: A
authors.lastname: Balder
authors.forename: E C
authors.initials: EC
authors.lastname: Stein
authors.forename: L
authors.initials: L
authors.lastname: Byrne
mesh_terms: D000328:Adult; D001521:Behavior Therapy; D001794:Blood Pressure / Q000187:drug effects; D003131:Combined Modality Therapy; D004038:Diet, Reducing; D004359:Drug Therapy, Combination; D015444:Exercise; D005260:Female; D005277:Fenfluramine / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000628:therapy*; D010645:Phentermine / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors; D015431:Weight Loss
chemical_list: D005277:Fenfluramine; D010645:Phentermine